BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada ...

This week, Tandem Diabetes Care’s t:slim X2 insulin pump and Control-IQ algorithm made headlines as they became the first to integrate with Dexcom’s G7 sensor to create an artificial pancreas system.

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people with diabetes.

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

One of the most anticipated devices in medtech has finally won a nod from FDA. Dexcom closes out 2022 with clearance for the G7 Continuous Glucose Monitor after facing a few delays. The device is ...

This healthcare technology company is disrupting the diabetes market with innovative technologies that patients love. More than 34 million Americans have diabetes and an additional 88 million are at ...

Dexcom G7 is the most accurate CGM system1 approved by Health Canada, building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hypoglycemia, and improve time ...